Open Access
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
1
2
Publication type: Journal Article
Publication date: 2007-08-13
scimago Q1
wos Q1
SJR: 2.489
CiteScore: 15.4
Impact factor: 7.3
ISSN: 09509232, 14765594
PubMed ID:
17700533
Cancer Research
Molecular Biology
Genetics
Abstract
Nutlin-3, a small molecule inhibitor, activates p53 by disrupting p53-HDM2 association. In this study, we found that Nutlin-3 suppressed cell growth and induced apoptosis in the absence of wild-type p53, suggesting a p53-independent mechanism for Nutlin-3-induced cell death. Like p53, its homolog p73 transactivates proapoptotic genes and induces cell death. Since HDM2, a key negative regulator of p53, also binds to and inhibits p73, we asked whether p73 could mediate Nutlin-3-induced apoptosis. We demonstrate that Nutlin-3 inhibits endogenous binding between the proapoptotic p73 isoform TAp73α and HDM2 in p53-null cells. Dissociation of p73 and HDM2 leads to increased p73 transcriptional activity with upregulation of p73 target genes noxa, puma and p21, as well as enhanced apoptosis. p73 knockdown by siRNA results in rescue of Nutlin-3-treated cells, indicating that Nutlin-3-induced apoptosis is, at least in part, p73 dependent. In addition, Nutlin-3 treatment increases TAp73α protein levels with prolongation of p73 half-life. These results provide the first evidence that Nutlin-3 disrupts endogenous p73–HDM2 interaction and enhances the stability and proapoptotic activities of p73 and thus, provides a rationale for the use of Nutlin-3 in the large number of human tumors in which p53 is inactivated.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
6
|
|
|
Oncotarget
6 publications, 4.03%
|
|
|
Oncogene
5 publications, 3.36%
|
|
|
Leukemia
5 publications, 3.36%
|
|
|
Journal of Hematology and Oncology
4 publications, 2.68%
|
|
|
Cell Death and Disease
4 publications, 2.68%
|
|
|
Cancer Letters
4 publications, 2.68%
|
|
|
Clinical Cancer Research
4 publications, 2.68%
|
|
|
International Journal of Molecular Sciences
3 publications, 2.01%
|
|
|
Cancers
3 publications, 2.01%
|
|
|
Frontiers in Oncology
3 publications, 2.01%
|
|
|
Molecular Cancer
3 publications, 2.01%
|
|
|
European Journal of Cancer
3 publications, 2.01%
|
|
|
Expert Opinion on Therapeutic Targets
3 publications, 2.01%
|
|
|
Cancer Research
3 publications, 2.01%
|
|
|
International Journal of Oncology
2 publications, 1.34%
|
|
|
Apoptosis : an international journal on programmed cell death
2 publications, 1.34%
|
|
|
Cell Death Discovery
2 publications, 1.34%
|
|
|
PLoS ONE
2 publications, 1.34%
|
|
|
Journal of Biological Chemistry
2 publications, 1.34%
|
|
|
Seminars in Cancer Biology
2 publications, 1.34%
|
|
|
Journal of Cellular Biochemistry
2 publications, 1.34%
|
|
|
Cancer Science
2 publications, 1.34%
|
|
|
Molecular Cancer Therapeutics
2 publications, 1.34%
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
2 publications, 1.34%
|
|
|
Current Drug Targets
1 publication, 0.67%
|
|
|
Future Oncology
1 publication, 0.67%
|
|
|
Journal of Medicinal Food
1 publication, 0.67%
|
|
|
Biochemical Society Transactions
1 publication, 0.67%
|
|
|
Hepatology
1 publication, 0.67%
|
|
|
1
2
3
4
5
6
|
Publishers
|
5
10
15
20
25
30
35
40
|
|
|
Springer Nature
37 publications, 24.83%
|
|
|
Elsevier
28 publications, 18.79%
|
|
|
Wiley
13 publications, 8.72%
|
|
|
American Association for Cancer Research (AACR)
11 publications, 7.38%
|
|
|
Taylor & Francis
9 publications, 6.04%
|
|
|
MDPI
9 publications, 6.04%
|
|
|
Impact Journals
6 publications, 4.03%
|
|
|
Frontiers Media S.A.
4 publications, 2.68%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 2.01%
|
|
|
Spandidos Publications
2 publications, 1.34%
|
|
|
Public Library of Science (PLoS)
2 publications, 1.34%
|
|
|
American Society for Biochemistry and Molecular Biology
2 publications, 1.34%
|
|
|
American Chemical Society (ACS)
2 publications, 1.34%
|
|
|
Royal Society of Chemistry (RSC)
2 publications, 1.34%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 1.34%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.67%
|
|
|
Mary Ann Liebert
1 publication, 0.67%
|
|
|
Portland Press
1 publication, 0.67%
|
|
|
Journal of Neurosurgery Publishing Group (JNSPG)
1 publication, 0.67%
|
|
|
Second Military Medical University Press
1 publication, 0.67%
|
|
|
SAGE
1 publication, 0.67%
|
|
|
Neoplasia Press
1 publication, 0.67%
|
|
|
American Society for Microbiology
1 publication, 0.67%
|
|
|
SciELO
1 publication, 0.67%
|
|
|
Oxford University Press
1 publication, 0.67%
|
|
|
American Society of Hematology
1 publication, 0.67%
|
|
|
Cambridge University Press
1 publication, 0.67%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 0.67%
|
|
|
Pleiades Publishing
1 publication, 0.67%
|
|
|
5
10
15
20
25
30
35
40
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
149
Total citations:
149
Citations from 2025:
8
(5.37%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Lau L. M. S. et al. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function // Oncogene. 2007. Vol. 27. No. 7. pp. 997-1003.
GOST all authors (up to 50)
Copy
Lau L. M. S., Nugent J. K., Zhao X., Irwin M. S. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function // Oncogene. 2007. Vol. 27. No. 7. pp. 997-1003.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1038/sj.onc.1210707
UR - https://doi.org/10.1038/sj.onc.1210707
TI - HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
T2 - Oncogene
AU - Lau, L M S
AU - Nugent, J K
AU - Zhao, X.
AU - Irwin, M S
PY - 2007
DA - 2007/08/13
PB - Springer Nature
SP - 997-1003
IS - 7
VL - 27
PMID - 17700533
SN - 0950-9232
SN - 1476-5594
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2007_Lau,
author = {L M S Lau and J K Nugent and X. Zhao and M S Irwin},
title = {HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function},
journal = {Oncogene},
year = {2007},
volume = {27},
publisher = {Springer Nature},
month = {aug},
url = {https://doi.org/10.1038/sj.onc.1210707},
number = {7},
pages = {997--1003},
doi = {10.1038/sj.onc.1210707}
}
Cite this
MLA
Copy
Lau, L. M. S., et al. “HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.” Oncogene, vol. 27, no. 7, Aug. 2007, pp. 997-1003. https://doi.org/10.1038/sj.onc.1210707.